Robert Nadler, MD
Urology · Springfield, ILNPI 1982623401
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,700 of the $70,474 with a category attached, or 89.0%. Travere Therapeutics, Inc. accounts for 94.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $27,078 and has fallen 95.9% since, to $1,111 in 2025. Among urology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $443.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$67K
- Boston Scientific$1K
- Procept Biorobotics Corporation$608
- Johnson & Johnson$258
- Coloplast$216
- Urogen Pharma, Inc.$214
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$62,70089%
- Travel & lodging$7791%
- Food & beverage$6,96010%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 67 | $66,818 |
| Boston Scientific | 16 | $1,078 |
| Procept Biorobotics Corporation | 8 | $608 |
| Johnson & Johnson(2 entities) | 8 | $258 |
| Coloplast | 7 | $216 |
| Urogen Pharma, Inc. | 3 | $214 |
| Sumitomo Pharma America, Inc. | 5 | $203 |
| Ferring Pharmaceuticals Inc. | 8 | $177 |
| Merck | 5 | $113 |
| AstraZeneca | 3 | $76 |
| Olympus America Inc. | 3 | $76 |
| Pfizer | 3 | $62 |
| Medtronic | 1 | $62 |
| Olympus Corporation Of The Americas | 1 | $61 |
| AbbVie | 3 | $58 |
| Cook Medical LLC | 3 | $51 |
| Dendreon Pharmaceuticals LLC | 1 | $49 |
| Intuitive Surgical | 1 | $46 |
| Myriad Genetic Laboratories, Inc. | 2 | $39 |
| Neotract Inc. | 1 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| 180 Medical, Inc. | 1 | $25 |
| Ambu Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $21 |
| Profound Medical Corp. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| ABC Home Medical Supply, Inc. | 1 | $14 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (815) Thiola$66,280
- LithoVue$617
- AquaBeam Robotic System$258
- GEMTESA$123
- RYBREVANT$121
- CARVYKTI$121
- AQUABEAM SYSTEM$104
- JELMYTO$103
How this compares
$70,474 in reported general payments places this provider in the 95th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 28 | $14,600 |
| GemtesaVibegron | 15 | $10,640 |
| LithostatAcetohydroxamic Acid | 12 | $8,428 |
| Tamsulosin Hcl | 193 | $2,241 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $757 |
| Finasteride | 54 | $507 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $505 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 27 | $485 |
| Amiloride-HydrochlorothiazideAmiloride/Hydrochlorothiazide | 12 | $358 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 225 | $235 |
| Cephalexin | 47 | $207 |
| Ciprofloxacin Hcl | 113 | $168 |
| Oxybutynin Chloride | 13 | $151 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $29 | $14,60028 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $203 | $10,64015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 550 urology providers in Illinois.
Other urology in Springfield
- Kevin McVarySpringfield$372K
- Bradley SchwartzSpringfield$45K
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.